Literature DB >> 7273513

Mesenchymal chondrosarcoma: a report of 17 cases.

A R Harwood, J I Krajbich, V L Fornasier.   

Abstract

Mesenchymal chondrosarcoma is a rare, almost uniformally lethal variant of chondrosarcoma which has been regarded as resistant to chemotherapy and radiotherapy. Seventeen cases are reported; 14 are dead of tumor or still alive with disease; eight of the 14 died less than one year after treatment, predominately of distant metastatic disease. This confirms previous reports of the highly aggressive nature of mesenchymal chondrosarcoma. Although surgery is regarded as the major method of treating the primary disease, it has limitations because many tumors cannot be adequately removed owing to location or extension to unresectable sites. It was found that such tumors respond to irradiation and that a combination of chemotherapy and radiotherapy should be used in unresectable tumors or those resected with inadequate margins. Adjuvant chemotherapy is advised in all cases treated with radical surgical excision. Unfavorable prognostic factors in mesenchymal chondrosarcoma are pain as a presenting symptom and a central rather than a peripheral limb location.

Entities:  

Mesh:

Year:  1981        PMID: 7273513

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  19 in total

1.  Morphological typing of chondrosarcoma: a study of 94 cases.

Authors:  H Welkerling; T Dreyer; G Delling
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Femoral mesenchymal chondrosarcoma with secondary aneurysmal bone cysts mimicking a small-cell osteosarcoma.

Authors:  Shalini A Amukotuwa; Peter F M Choong; Peter J Smith; Gerard J Powell; David Thomas; Stephen M Schlicht
Journal:  Skeletal Radiol       Date:  2005-11-18       Impact factor: 2.199

3.  Paraspinal mass in a child.

Authors:  S Berberoglu; M E Aribal; U Arikan; A Ince
Journal:  Postgrad Med J       Date:  1996-08       Impact factor: 2.401

4.  Intra-parenchymal mesenchymal chondrosarcoma of the cerebellum: case report and review of the literature.

Authors:  Michael Yassa; Jean-Paul Bahary; Pierre Bourguoin; Manon Bélair; France Berthelet; Alain Bouthillier
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

5.  A rare cause of spinal cord compression in childhood from intraspinal mesenchymal chondrosarcoma. A report of two cases and review of the literature.

Authors:  H S Chan; S O Turner-Gomes; S H Chuang; C R Fitz; A Daneman; D J Martin; L E Becker
Journal:  Neuroradiology       Date:  1984       Impact factor: 2.804

6.  Radiation therapy is associated with fewer recurrences in mesenchymal chondrosarcoma.

Authors:  Satoshi Kawaguchi; Israel Weiss; Patrick P Lin; Winston W Huh; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

7.  [First description of mesenchymal chondrosarcoma of the lateral skull base in a 9-year-old boy].

Authors:  A Glien; O Moser; F Göke; K Wilhelm; A O H Gerstner
Journal:  HNO       Date:  2012-12       Impact factor: 1.284

8.  Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

Authors:  Yvonne de Jong; Annemiek M van Maldegem; Adrian Marino-Enriquez; Danielle de Jong; Johnny Suijker; Inge H Briaire-de Bruijn; Alwine B Kruisselbrink; Anne-Marie Cleton-Jansen; Karoly Szuhai; Hans Gelderblom; Jonathan A Fletcher; Judith V M G Bovée
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

Review 9.  Intracranial chondrosarcoma: a case report and review of the literature.

Authors:  James P Chandler; Parham Yashar; William B Laskin; Eric J Russell
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

Review 10.  Intracranial mesenchymal chondrosarcoma: a case report and literature review.

Authors:  B K Cho; J G Chi; K C Wang; K H Chang; K S Choi
Journal:  Childs Nerv Syst       Date:  1993-08       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.